Defining genome-wide CRISPR-Cas genome-editing nuclease activity with GUIDE-seq.


Journal

Nature protocols
ISSN: 1750-2799
Titre abrégé: Nat Protoc
Pays: England
ID NLM: 101284307

Informations de publication

Date de publication:
12 2021
Historique:
received: 31 10 2020
accepted: 02 09 2021
pubmed: 14 11 2021
medline: 24 12 2021
entrez: 13 11 2021
Statut: ppublish

Résumé

Genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) is a sensitive, unbiased, genome-wide method for defining the activity of genome-editing nucleases in living cells. GUIDE-seq is based on the principle of efficient integration of an end-protected double-stranded oligodeoxynucleotide tag into sites of nuclease-induced DNA double-stranded breaks, followed by amplification of tag-containing genomic DNA molecules and high-throughput sequencing. Here we describe a detailed GUIDE-seq protocol including cell transfection, library preparation, sequencing and bioinformatic analysis. The entire protocol including cell culture can be completed in 9 d. Once tag-integrated genomic DNA is isolated, library preparation, sequencing and analysis can be performed in 3 d. The result is a genome-wide catalog of off-target sites ranked by nuclease activity as measured by GUIDE-seq read counts. GUIDE-seq is one of the most sensitive cell-based methods for defining genome-wide off-target activity and has been broadly adopted for research and therapeutic use.

Identifiants

pubmed: 34773119
doi: 10.1038/s41596-021-00626-x
pii: 10.1038/s41596-021-00626-x
pmc: PMC9331158
mid: NIHMS1811119
doi:

Substances chimiques

DNA Primers 0
RNA, Guide 0
CRISPR-Associated Protein 9 EC 3.1.-
Cas9 endonuclease Streptococcus pyogenes EC 3.1.-
endodeoxyribonuclease NdeI EC 3.1.21.-
Deoxyribonucleases, Type II Site-Specific EC 3.1.21.4

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5592-5615

Subventions

Organisme : NIGMS NIH HHS
ID : DP1 GM105378
Pays : United States
Organisme : Doris Duke Charitable Foundation
ID : 2020154
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI157189
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM088040
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR063070
Pays : United States
Organisme : Doris Duke Charitable Foundation
ID : 2017093
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Maeder, M. L. & Gersbach, C. A. Genome-editing technologies for gene and cell therapy. Mol. Ther. 24, 430–446 (2016).
doi: 10.1038/mt.2016.10
Wang, H., Russa, M. L. & Qi, L. S. CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 1–38 (2015).
Anderson, K. R. et al. CRISPR off-target analysis in genetically engineered rats and mice. Nat. Methods https://doi.org/10.1038/s41592-018-0011-5 (2018).
Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2015).
doi: 10.1038/nbt.3117
Xie, K. & Yang, Y. RNA-guided genome editing in plants using a CRISPR–Cas system. Mol. Plant 6, 1975–1983 (2013).
doi: 10.1093/mp/sst119
Cheng, Y. & Tsai, S. Q. Illuminating the genome-wide activity of genome editors for safe and effective therapeutics. Genome Biol. 19, 226 (2018).
doi: 10.1186/s13059-018-1610-2
Putney, S., Benkovic, S. & Schimmel, P. A DNA fragment with an alpha-phosphorothioate nucleotide at one end is asymmetrically blocked from digestion by exonuclease III and can be replicated in vivo. Proc. Natl Acad. Sci. 78, 7350–7354 (1981).
doi: 10.1073/pnas.78.12.7350
Lazzarotto, C. R. et al. CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity. Nat. Biotechnol. 38, 1317–1327 (2020).
doi: 10.1038/s41587-020-0555-7
Zheng, Z. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479–1484 (2014).
doi: 10.1038/nm.3729
Tsai, S. Q., Topkar, V. V., Joung, K. J. & Aryee, M. J. Open-source guideseq software for analysis of GUIDE-seq data. Nat. Biotechnol. 34, 483–483 (2016).
doi: 10.1038/nbt.3534
Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat. Methods 14, 607–614 (2017).
doi: 10.1038/nmeth.4278
Wienert, B. et al. Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq. Science 364, 286–289 (2019).
doi: 10.1126/science.aav9023
Wang, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175–178 (2015).
doi: 10.1038/nbt.3127
Kim, D. et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12, 237–243 (2015).
doi: 10.1038/nmeth.3284
Yan, W. X. et al. BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks. Nat. Commun. 8, 15058 (2017).
doi: 10.1038/ncomms15058
Schmid-Burgk, J. L. et al. Highly parallel profiling of Cas9 variant specificity. Mol. Cell 78, 794–800.e8 (2020).
doi: 10.1016/j.molcel.2020.02.023
Crosetto, N. et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat. Methods 10, 361–365 (2013).
doi: 10.1038/nmeth.2408
Wang, L. et al. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nat. Biotechnol. 36, 717–725 (2018).
doi: 10.1038/nbt.4182
Miller, J. C. et al. Enhancing gene editing specificity by attenuating DNA cleavage kinetics. Nat. Biotechnol. 37, 945–952 (2019).
doi: 10.1038/s41587-019-0186-z
Kleinstiver, B. et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat. Biotechnol. 34, 869.
Nobles, C. L. et al. iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome Biol. 20, 14 (2019).
doi: 10.1186/s13059-019-1625-3
Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science https://doi.org/10.1126/science.aba8853 (2020).
Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).
doi: 10.1038/nbt.3290
Fiume, M. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).
doi: 10.1038/s41587-019-0032-3

Auteurs

Nikolay L Malinin (NL)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

GaHyun Lee (G)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Cicera R Lazzarotto (CR)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Yichao Li (Y)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Zongli Zheng (Z)

Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.

Nhu T Nguyen (NT)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.

Matthew Liebers (M)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.

Ved V Topkar (VV)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
Biophysics Program, Stanford University, Stanford, CA, USA.

A John Iafrate (AJ)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.

Long P Le (LP)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.

Martin J Aryee (MJ)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.

J Keith Joung (JK)

Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.

Shengdar Q Tsai (SQ)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA. shengdar.tsai@stjude.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH